Skip to main content
Erschienen in: World Journal of Urology 10/2019

22.01.2019 | Original Article

A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer

verfasst von: Boris Gershman, Paul Maroni, Jon C. Tilburt, Robert J. Volk, Badrinath Konety, Charles L. Bennett, Alexander Kutikov, Marc C. Smaldone, Victor Chen, Simon P. Kim

Erschienen in: World Journal of Urology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although prediction tools for prostate cancer (PCa) are essential for high-quality treatment decision-making, little is known about the degree of confidence in existing tools and whether they are used in clinical practice from radiation oncologists (RO) and urologists (URO). Herein, we performed a national survey of specialists about perceived attitudes and use of prediction tools.

Methods

In 2017, we invited 940 URO and 911 RO in a national survey to query their confidence in and use of the D’Amico criteria, Kattan Nomogram, and CAPRA score. The statistical analysis involved bivariate association and multivariable logistic regression analyses to identify physician characteristics (age, gender, race, practice affiliation, specialty, access to robotic surgery, ownership of linear accelerator and number of prostate cancer per week) associated with survey responses and use of active surveillance (AS) for low-risk PCa.

Results

Overall, 691 (37.3%) specialists completed the surveys. Two-thirds (range 65.6–68.4%) of respondents reported being “somewhat confident”, but only a fifth selected “very confident” for each prediction tool (18.0–20.1%). 19.1% of specialists in the survey reported not using any prediction tools in clinical practice, which was higher amongst URO than RO (23.9 vs. 13.4%; p < 0.001). Respondents who reported not using prediction tools were also associated with low utilization of AS in their low-risk PCa patients (adjusted OR 2.47; p = 0.01).

Conclusions

While a majority of RO and URO view existing prediction tools for localized PCa with some degree of confidence, a fifth of specialists reported not using any such tools in clinical practice. Lack of using such tools was associated with low utilization of AS for low-risk PCa.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mohler JL, Armstrong AJ, Bahnson RR et al (2016) Prostate cancer, version 1.2016. J Natl Compr Canc Netw 14(1):19–30CrossRef Mohler JL, Armstrong AJ, Bahnson RR et al (2016) Prostate cancer, version 1.2016. J Natl Compr Canc Netw 14(1):19–30CrossRef
2.
Zurück zum Zitat Sanda MG, Cadeddu JA, Kirkby E et al (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 199(3):683–690CrossRef Sanda MG, Cadeddu JA, Kirkby E et al (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 199(3):683–690CrossRef
3.
Zurück zum Zitat Sanda MG, Cadeddu JA, Kirkby E et al (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 199(4):990–997CrossRef Sanda MG, Cadeddu JA, Kirkby E et al (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 199(4):990–997CrossRef
4.
Zurück zum Zitat Resnick MJ, Koyama T, Fan KH et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368(5):436–445CrossRef Resnick MJ, Koyama T, Fan KH et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368(5):436–445CrossRef
5.
Zurück zum Zitat Wilt TJ, Jones KM, Barry MJ et al (2017) Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377(2):132–142CrossRef Wilt TJ, Jones KM, Barry MJ et al (2017) Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377(2):132–142CrossRef
6.
Zurück zum Zitat Donovan JL, Hamdy FC, Lane JA et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425–1437CrossRef Donovan JL, Hamdy FC, Lane JA et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425–1437CrossRef
7.
Zurück zum Zitat Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424CrossRef Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424CrossRef
8.
Zurück zum Zitat Bekelman JE, Rumble RB, Chen RC et al (2018) Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 36(32):3251–3258 Bekelman JE, Rumble RB, Chen RC et al (2018) Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 36(32):3251–3258
9.
Zurück zum Zitat Ross PL, Scardino PT, Kattan MW (2001) A catalog of prostate cancer nomograms. J Urol 165(5):1562–1568CrossRef Ross PL, Scardino PT, Kattan MW (2001) A catalog of prostate cancer nomograms. J Urol 165(5):1562–1568CrossRef
10.
Zurück zum Zitat Rodrigues G, Warde P, Pickles T et al (2012) Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J 6(2):121–127CrossRef Rodrigues G, Warde P, Pickles T et al (2012) Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J 6(2):121–127CrossRef
11.
Zurück zum Zitat Stephenson AJ, Scardino PT, Eastham JA et al (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98(10):715–717CrossRef Stephenson AJ, Scardino PT, Eastham JA et al (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98(10):715–717CrossRef
12.
Zurück zum Zitat Kattan MW, Eastham JA, Wheeler TM et al (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170(5):1792–1797CrossRef Kattan MW, Eastham JA, Wheeler TM et al (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170(5):1792–1797CrossRef
13.
Zurück zum Zitat Kattan MW, Zelefsky MJ, Kupelian PA et al (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21(24):4568–4571CrossRef Kattan MW, Zelefsky MJ, Kupelian PA et al (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21(24):4568–4571CrossRef
14.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRef D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRef
15.
Zurück zum Zitat Cooperberg MR, Pasta DJ, Elkin EP et al (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173(6):1938–1942CrossRef Cooperberg MR, Pasta DJ, Elkin EP et al (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173(6):1938–1942CrossRef
16.
Zurück zum Zitat Cooperberg MR, Broering JM, Carroll PR (2009) Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101(12):878–887CrossRef Cooperberg MR, Broering JM, Carroll PR (2009) Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101(12):878–887CrossRef
17.
Zurück zum Zitat Otto BJ, Osterberg EC, Salgado S, Scherr DS, Shariat SF (2015) Prostate cancer risk estimation tool use by members of the American Urological Association: a survey based study. J Urol 193(6):1933–1937CrossRef Otto BJ, Osterberg EC, Salgado S, Scherr DS, Shariat SF (2015) Prostate cancer risk estimation tool use by members of the American Urological Association: a survey based study. J Urol 193(6):1933–1937CrossRef
18.
Zurück zum Zitat Kim SP, Karnes RJ, Nguyen PL et al (2013) Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol 189(6):2092–2098CrossRef Kim SP, Karnes RJ, Nguyen PL et al (2013) Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol 189(6):2092–2098CrossRef
19.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629CrossRef Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629CrossRef
20.
Zurück zum Zitat Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8(2):162–200CrossRef Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8(2):162–200CrossRef
21.
Zurück zum Zitat Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113(11):3075–3099CrossRef Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113(11):3075–3099CrossRef
22.
Zurück zum Zitat Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18(19):3352–3359CrossRef Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18(19):3352–3359CrossRef
23.
Zurück zum Zitat Stephenson AJ, Kattan MW, Eastham JA et al (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27(26):4300–4305CrossRef Stephenson AJ, Kattan MW, Eastham JA et al (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27(26):4300–4305CrossRef
24.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (1999) Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17(1):168–172CrossRef D’Amico AV, Whittington R, Malkowicz SB et al (1999) Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17(1):168–172CrossRef
25.
Zurück zum Zitat Kim SP, Gross CP, Nguyen PL et al (2014) Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis 17(2):163–169CrossRef Kim SP, Gross CP, Nguyen PL et al (2014) Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis 17(2):163–169CrossRef
26.
Zurück zum Zitat Kim SP, Tilburt JC, Karnes RJ et al (2013) Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology 82(4):807–812CrossRef Kim SP, Tilburt JC, Karnes RJ et al (2013) Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology 82(4):807–812CrossRef
27.
Zurück zum Zitat Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ (2000) Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283(24):3217–3222CrossRef Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ (2000) Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283(24):3217–3222CrossRef
28.
Zurück zum Zitat Sommers BD, Beard CJ, D’Amico AV, Kaplan I, Richie JP, Zeckhauser RJ (2008) Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113(8):2058–2067CrossRef Sommers BD, Beard CJ, D’Amico AV, Kaplan I, Richie JP, Zeckhauser RJ (2008) Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113(8):2058–2067CrossRef
29.
Zurück zum Zitat Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101(19):1325–1329CrossRef Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101(19):1325–1329CrossRef
30.
Zurück zum Zitat Cooperberg MR (2015) Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol 33(3):238–240CrossRef Cooperberg MR (2015) Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol 33(3):238–240CrossRef
31.
Zurück zum Zitat Kim SP, Gross CP, Nguyen PL et al (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: results from a national survey of radiation oncologists and urologists. Med Care 52(7):579–585CrossRef Kim SP, Gross CP, Nguyen PL et al (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: results from a national survey of radiation oncologists and urologists. Med Care 52(7):579–585CrossRef
32.
Zurück zum Zitat Zeliadt SB, Ramsey SD, Penson DF et al (2006) Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 106(9):1865–1874CrossRef Zeliadt SB, Ramsey SD, Penson DF et al (2006) Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 106(9):1865–1874CrossRef
33.
Zurück zum Zitat Shariat SF, Karakiewicz PI, Suardi N, Kattan MW (2008) Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 14(14):4400–4407CrossRef Shariat SF, Karakiewicz PI, Suardi N, Kattan MW (2008) Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 14(14):4400–4407CrossRef
Metadaten
Titel
A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer
verfasst von
Boris Gershman
Paul Maroni
Jon C. Tilburt
Robert J. Volk
Badrinath Konety
Charles L. Bennett
Alexander Kutikov
Marc C. Smaldone
Victor Chen
Simon P. Kim
Publikationsdatum
22.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 10/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02637-6

Weitere Artikel der Ausgabe 10/2019

World Journal of Urology 10/2019 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.